Literature DB >> 1919642

Medulloblastoma: tumor biological and clinical perspectives.

H S Friedman1, W J Oakes, S H Bigner, C J Wikstrand, D D Bigner.   

Abstract

Medulloblastoma is the most common central nervous system malignancy of childhood, with approximately 350 new cases seen in the United States each year. Although the low incidence of this tumor, compared with adult neoplasms such as breast or colon carcinoma, has limited laboratory and clinical research, recent studies have greatly enhanced our understanding of the biology, phenotype, genotype, and therapy of medulloblastoma. Further efforts to integrate laboratory and clinical studies of this tumor may allow design of novel therapeutic approaches resulting in enhanced disease-free survival.

Entities:  

Mesh:

Year:  1991        PMID: 1919642     DOI: 10.1007/bf00166992

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  80 in total

1.  Glioblastoma developing at the site of a cerebellar medulloblastoma treated 6 years earlier. Case report.

Authors:  M Schmidbauer; H Budka; R Bruckner; P Vorkapic
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

Review 2.  Recent advances in the immunologic classification of leukemia.

Authors:  K A Foon; R P Gale; R F Todd
Journal:  Semin Hematol       Date:  1986-10       Impact factor: 3.851

3.  Prognostic importance of DNA ploidy in medulloblastoma of childhood.

Authors:  M Yasue; T Tomita; H Engelhard; F Gonzalez-Crussi; D G McLone; K D Bauer
Journal:  J Neurosurg       Date:  1989-03       Impact factor: 5.115

4.  Neonatal cerebellar medulloblastoma originating from the fetal external granular layer.

Authors:  M E Kadin; L J Rubinstein; J S Nelson
Journal:  J Neuropathol Exp Neurol       Date:  1970-10       Impact factor: 3.685

Review 5.  Embryonal central neuroepithelial tumors and their differentiating potential. A cytogenetic view of a complex neuro-oncological problem.

Authors:  L J Rubinstein
Journal:  J Neurosurg       Date:  1985-06       Impact factor: 5.115

6.  Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation.

Authors:  K Tamura; K Shimizu; M Yamada; Y Okamoto; Y Matsui; K C Park; E Mabuchi; S Moriuchi; H Mogami
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

7.  Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins.

Authors:  V E Gould; D S Jansson; W M Molenaar; L B Rorke; J Q Trojanowski; V M Lee; R J Packer; W W Franke
Journal:  Lab Invest       Date:  1990-04       Impact factor: 5.662

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.

Authors:  J C Allen; L Helson
Journal:  J Neurosurg       Date:  1981-11       Impact factor: 5.115

10.  Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management.

Authors:  G Kopelson; R M Linggood; G M Kleinman
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

View more
  9 in total

1.  Medulloblastoma: survival and late recurrence after the Collins' risk period.

Authors:  S Nishio; T Morioka; I Takeshita; M Fukui
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

2.  Medulloblastoma in pediatric age: a single-institution review of prognostic factors.

Authors:  L Cervoni; G Cantore
Journal:  Childs Nerv Syst       Date:  1995-02       Impact factor: 1.475

Review 3.  Cellular and molecular pathology of medulloblastoma.

Authors:  J P Provias; L E Becker
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

4.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.

Authors:  D K Strickland; G Vaidyanathan; H S Friedman; M R Zalutsky
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 6.  Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).

Authors:  H S Friedman; S H Bigner; D D Bigner
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain.

Authors:  Jianping Wang; Ngan Pham-Mitchell; Christian Schindler; Iain L Campbell
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Inherent variability of cancer-specific aneuploidy generates metastases.

Authors:  Mathew Bloomfield; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2016-12-16       Impact factor: 2.009

9.  Magnitude of Neurogenic Tumor Burden in Pediatric Population: A Tertiary Care Center Study.

Authors:  Shagufta Qadri; Mahboob Hasan; Kafil Akhtar
Journal:  J Pediatr Neurosci       Date:  2017 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.